Since 1998, OCRFA has awarded 255 grants totaling nearly $70 million for ovarian cancer research to top scientists at 69 leading medical centers. We invest our dollars wisely, supporting the best ovarian cancer research in the nation.
OCRFA-funded projects have led to significant advances in such areas as early detection, diagnosis, genetics, prevention, treatments, and enhancing quality of life. In just the past year, OCRFA funded researchers have:
- pinpointed two genes that trigger ovarian cancer
- identified a new therapeutic strategy for clear cell ovarian cancer
- shown how a PARP/immune therapy combo shows promise
- demonstrated how gene therapy may help patients with recurrent disease
- confirmed generic heart medication can prolong survival in ovarian cancer patients
- shed light on how ovarian cancer grows
The results of OCRFA-supported research projects have been published in some of the world’s most prestigious journals, such as: Gynecologic Oncology, Lancet Oncology, New England Journal of Medicine, Cancer Research, Clinical Cancer Research, Journal of Clinical Oncology, Science Translational Medicine, Cancer Discovery and Nature.